ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor? .......................... 35
J.N. Wu and C.W.M. Roberts

Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention .......................... 44
M. Loda, J.J. Zhao, and T.M. Roberts
Précis: Antiandrogen therapies promote prostate cancer progression, whereas blockade of PI3K and MAPK signaling suppresses tumor growth in the context of PTEN deficiency.

Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening .......................... 52
M.A. Held, C.G. Langdon, J.T. Platt, T. Graham-Steed, Z. Liu, A. Chakraborty,
A. Bacchiocchi, A. Koo, J.W. Haskins, M.W. Bosenberg, and D.F. Stern
See commentary, p. 14
Précis: A systematic screening approach was used to characterize inhibitor combinations that are effective in melanomas driven by specific oncogenic mutations.

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors .......................... 68
R. Drost, E. Wientjens, J. Ji, A. Aly, J.H. Doroshow, A. Cranston, N.M.B. Martin,
See commentary, p. 20
Précis: PARP inhibitor resistance can arise in vivo through partial restoration of homologous recombination caused by 53BP1 inactivation.
The mTORC1 Inhibitor Everolimus Prevents and Treats Eμ-Myc Lymphoma by Restoring Oncogene-Induced Senescence ................. 82
Précis: mTORC1-dependent bypass of MYC-induced senescence is required for the initiation and maintenance of Eμ-Myc B-cell lymphoma.

Targeting C4-Demethylating Genes in the Cholesterol Pathway Sensitizes Cancer Cells to EGF Receptor Inhibitors via Increased EGF Receptor Degradation ... 96
Précis: Sterol biosynthesis genes regulate EGFR endocytosis and signaling, and inhibition of these genes increases the efficacy of anti-EGFR therapies.

Correction
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development ................. 124
Young and colleagues show that oncogenic and wild-type RAS isoforms have nonredundant, independent roles in cancer cells. Oncogenic RAS isoforms desensitize cells to receptor tyrosine kinase (RTK) stimulation and promote basal mitogen-activated protein kinase (MAPK) signaling, whereas wild-type RAS isoforms are required for RTK-dependent activation of MAPK signaling and optimal growth of cancer cells expressing oncogenic RAS. Depletion of oncogenic RAS sensitizes cells to wild-type isoform-mediated growth factor signaling, uncovering a potential resistance mechanism employed by RAS-mutant cells. Combined inhibition of RAS and RTK signaling effectively blocks growth of cells expressing oncogenic RAS and may therefore be a potential approach to circumvent resistance. For details, please see the article by Young and colleagues on page 112.

ON THE COVER
Young and colleagues show that oncogenic and wild-type RAS isoforms have nonredundant, independent roles in cancer cells. Oncogenic RAS isoforms desensitize cells to receptor tyrosine kinase (RTK) stimulation and promote basal mitogen-activated protein kinase (MAPK) signaling, whereas wild-type RAS isoforms are required for RTK-dependent activation of MAPK signaling and optimal growth of cancer cells expressing oncogenic RAS. Depletion of oncogenic RAS sensitizes cells to wild-type isoform-mediated growth factor signaling, uncovering a potential resistance mechanism employed by RAS-mutant cells. Combined inhibition of RAS and RTK signaling effectively blocks growth of cells expressing oncogenic RAS and may therefore be a potential approach to circumvent resistance. For details, please see the article by Young and colleagues on page 112.

ON THE COVER
Young and colleagues show that oncogenic and wild-type RAS isoforms have nonredundant, independent roles in cancer cells. Oncogenic RAS isoforms desensitize cells to receptor tyrosine kinase (RTK) stimulation and promote basal mitogen-activated protein kinase (MAPK) signaling, whereas wild-type RAS isoforms are required for RTK-dependent activation of MAPK signaling and optimal growth of cancer cells expressing oncogenic RAS. Depletion of oncogenic RAS sensitizes cells to wild-type isoform-mediated growth factor signaling, uncovering a potential resistance mechanism employed by RAS-mutant cells. Combined inhibition of RAS and RTK signaling effectively blocks growth of cells expressing oncogenic RAS and may therefore be a potential approach to circumvent resistance. For details, please see the article by Young and colleagues on page 112.
CANCER DISCOVERY

3 (1)


Updated version
Access the most recent version of this article at:
http://cancerdiscovery.aacrjournals.org/content/3/1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and
Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pub@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.